Explore chapters and articles related to this topic
Preparation and characterization of solid lipid nanoparticles of furosemide using quality by design
Published in Particulate Science and Technology, 2018
Hasan Ali, Sandeep Kumar Singh
On the basis of research findings from the literature, we selected Furosemide (FRSM) as the potential drug candidate of choice for the fabrication of SLN (Figure 1). FRSM is approved as a diuretic for the treatment of hypertension and edema, caused by renal impairment and cardiac dysfunction (Granero et al. 2010). It is the anthranilic acid derivative and acts as a loop diuretic, available in the market as Lasix® (Wu and Benet 2005; Granero et al. 2010). The FRSM is a BCS class IV category drug candidate. It shows low aqueous and pH-dependent solubility, low permeability and variable intersubject bioavailability (Shin and Kim 2003; Wu and Benet 2005; Granero et al. 2010).